Roche: collaboration with Zealand Pharma

(CercleFinance.com) - Roche announces that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialize petrelintide as a potential pivotal treatment for overweight and obese people.


The agreement enables a range of potentially first-in-class therapeutic options, such as monotherapy and fixed-dose combination with Roche's lead active CT 388, the Swiss healthcare group says.

Under the agreed terms, Zealand Pharma will receive upfront payments of $1.65bn, and will be eligible for development milestone payments of $1.2bn and sales-based milestone payments of $2.4bn.

The deal's completion is subject to regulatory approvals and other customary conditions. The parties expect the transaction to close in Q2 2025.


Copyright (c) 2025 CercleFinance.com. All rights reserved.